Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Lowered by ValuEngine

ValuEngine downgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a buy rating to a hold rating in a report published on Monday morning, ValuEngine reports.

RARE has been the subject of a number of other research reports. Morgan Stanley initiated coverage on shares of in a report on Monday, June 17th. They set an equal weight rating and a GBX 215 ($2.81) price target for the company. Wedbush reiterated a hold rating and issued a $9.00 target price on shares of Glu Mobile in a report on Tuesday, May 7th. Barclays reiterated a buy rating on shares of Ultragenyx Pharmaceutical in a report on Thursday, May 9th. BidaskClub downgraded shares of Xilinx from a buy rating to a hold rating in a report on Saturday, June 15th. Finally, Zacks Investment Research downgraded shares of Guaranty Federal Bancshares from a hold rating to a sell rating in a report on Tuesday, April 23rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $78.56.

Shares of NASDAQ RARE opened at $58.68 on Monday. The business’s 50 day moving average price is $59.37. The firm has a market cap of $3.27 billion, a P/E ratio of -7.94 and a beta of 2.17. The company has a debt-to-equity ratio of 0.03, a current ratio of 11.77 and a quick ratio of 11.60. Ultragenyx Pharmaceutical has a 1 year low of $37.44 and a 1 year high of $90.98.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.73) by ($0.09). The firm had revenue of $18.17 million for the quarter, compared to analyst estimates of $18.75 million. Ultragenyx Pharmaceutical had a negative return on equity of 51.00% and a negative net margin of 550.30%. The firm’s quarterly revenue was up 70.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.63 EPS. As a group, equities research analysts forecast that Ultragenyx Pharmaceutical will post -6.99 earnings per share for the current fiscal year.

In related news, EVP Karah Herdman Parschauer sold 1,226 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $61.50, for a total value of $75,399.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 3,183 shares of company stock valued at $201,185 in the last quarter. 7.80% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of RARE. Meeder Asset Management Inc. boosted its position in Ultragenyx Pharmaceutical by 321.1% in the 1st quarter. Meeder Asset Management Inc. now owns 598 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 456 shares during the period. First Mercantile Trust Co. boosted its position in Ultragenyx Pharmaceutical by 101.0% in the 1st quarter. First Mercantile Trust Co. now owns 985 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 495 shares during the period. Exane Derivatives boosted its position in Ultragenyx Pharmaceutical by 95.7% in the 1st quarter. Exane Derivatives now owns 1,601 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 783 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Ultragenyx Pharmaceutical by 19.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,303 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 379 shares during the period. Finally, Two Sigma Securities LLC purchased a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $209,000.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

See Also: What is the Federal Reserve?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.